Hemin-lipid assembly as an artemisinin oral delivery system for enhanced cancer chemotherapy and immunotherapy
Qing Wang, Naijie Wei, Jingru Guo, Kai Feng, Yin Kwan Wong, Jingwei Zhang, Jigang Wang, Xiaolian Sun
Abstract
ART in total) every other day and intraperitoneal injection with a programmed death-ligand 1 antibody (aPD-L1, 70 μg per mouse in total), MC38 tumors were completely inhibited within 30 days. The cured mice remained tumor-free 30 days after rechallenging them with another inoculation of MC38 cells due to the strong immune memory effect.
Topics & Concepts
ArtemisininHeminLiposomeDrug deliveryDrugPharmacologyCancerChemotherapyCancer researchPlasmodium falciparumChemistryMedicineMalariaNanotechnologyMaterials scienceBiochemistryImmunologyInternal medicineEnzymeHemeNanoparticle-Based Drug DeliveryMonoclonal and Polyclonal Antibodies ResearchHIV Research and Treatment